Revealing liver micrometastases in vivo using ultra-high definition MRI

MicroMetSCAN aims to revolutionize MRI techniques for early detection of liver micrometastases, enhancing cancer diagnosis and treatment through improved imaging sensitivity and biological insights.

Subsidie
€ 1.998.456
2025

Projectdetails

Introduction

Over 90% of cancer-related deaths are caused by metastases. A major obstacle for accurate patient stratification, development of new treatments against metastases, and thorough biological understanding is our inability to detect early-stage micrometastases (µMets). The liver is one of the first and most common sites for metastases, particularly in gastrointestinal tract tumours. Thus, early detection of liver metastases is an urgent need in cancer diagnosis for many patients.

Current Limitations

Present image-based diagnostic methods, including state-of-the-art Magnetic Resonance Imaging (MRI), cannot detect µMets due to major limitations in current image contrast and resolution, as well as a lack of understanding of liver tissue changes during the metastatic process.

Proposed Solution

MicroMetSCAN proposes a paradigm-shifting MRI approach based on highly promising preliminary results that leverage recent progress in MRI acquisition, denoising, and contrast generation. This approach aims to achieve the breakthrough of exquisite sensitivity and specificity required to detect and characterise μMets in the liver and provide new insights about metastases-related tissue microenvironment dynamics.

Objectives

To achieve its overarching goal, my proposal consists of four objectives:

  1. Developing new ultra-high resolution MRI methods targeting robust µMets detection.
  2. Tailoring the specificity of contrasts towards μMet environments.
  3. Unravelling the transformations from µMets to full metastases in animal models, yielding critical insights into tumour growth patterns.
  4. Translating the new MRI approach to the clinic in a prospective clinical study.

Impact

MicroMetSCAN will significantly advance the state-of-the-art in cancer imaging, enabling precision diagnosis and treatment planning, with wide-reaching applicability, especially benefitting small lesion detection. Furthermore, it will unveil important biological insights on the progression of metastasis, guiding future therapeutic strategies for better prognosis and outcomes.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.998.456
Totale projectbegroting€ 1.998.456

Tijdlijn

Startdatum1-4-2025
Einddatum31-3-2030
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • KING'S COLLEGE LONDONpenvoerder

Land(en)

United Kingdom

Vergelijkbare projecten binnen European Research Council

ERC Synergy ...

Treating Liver Metastasis

This project aims to enhance immunotherapy for colorectal liver metastases by targeting innate immune responses, utilizing advanced models to identify key cellular interactions and functions.

€ 10.180.358
ERC Proof of...

AI to predict Cancer metastasis using Ultra-Echo-Sono imaging

AI CUrES aims to enhance early diagnosis and pre-emptive therapies for cancer metastasis by utilizing nanosized-contrast agents and AI-driven bioimaging of extracellular vesicles from colorectal tumors.

€ 150.000
ERC Starting...

Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI

Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.

€ 1.497.669
ERC Consolid...

Deuterium labeling of GLUCOse improves magnetic resonance imaging Sensitivity to CANcer metabolism

GLUCO-SCAN aims to develop and clinically evaluate a novel whole-body deuterium metabolic imaging (DMI) method for cancer assessment, overcoming PET's limitations and enabling widespread screening.

€ 2.495.924
ERC Starting...

Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics

The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.

€ 2.481.640

Vergelijkbare projecten uit andere regelingen

EIC Transition

MIRACLE the platform for virtual biopsies; introducing Metabolic MRI-as-a-Service for oncologic care

MIRACLE aims to develop a non-invasive MRI add-on for virtual biopsies, enabling personalized cancer treatment decisions by providing structural and metabolic tumor information globally.

€ 2.495.127
EIC Transition

Non-ionizing Metabolic Imaging for predicting the effect of and guiding Therapeutic Interventions

MITI aims to develop advanced non-invasive metabolic imaging technology for early disease detection and therapy effectiveness assessment, improving patient outcomes and reducing healthcare costs.

€ 2.100.238
EIC Pathfinder

NEW TECHNOLOGY FOR 1 MICRON RESOLUTION BIOMEDICAL IMAGING

The 1MICRON project aims to revolutionize cancer detection by developing high-resolution, integrated x-ray sensors for immediate surgical feedback, potentially saving over 100,000 treatments annually in Europe.

€ 2.999.999
EIC Transition

Early detection of treatment response in breast cancer

The project aims to enhance breast cancer treatment through Hyperpolarized Magnetic Resonance imaging for early detection of non-responders, improving outcomes and reducing side effects.

€ 2.499.229